GlassScriptPhysician profile
Jess T Roy
NPI 1003889551
$14,900.12
in general payments reported to CMS, 2019-2025
53 companies · $4,296 in 2025
The $4,296 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $685 · 2021: $1,533 · 2022: $2,022 · 2023: $1,501 · 2024: $3,699 · 2025: $4,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,495.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,755.85 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,228.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $998.05 | 2023-2025 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $975.92 | 2019-2025 | Zoryve |
| Glaxosmithkline, LLC. | $970.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $881.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $753.94 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $703.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $675.32 | 2021-2025 | Jardiance, Ofev, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $437.79 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.55 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Abbott Laboratories | $376.70 | 2020-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $342.68 | 2024-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $338.09 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $306.24 | 2022-2025 | Spravato, Xarelto |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $302.28 | 2019-2025 | Verquvo |
| Biohaven Pharmaceutical Holding Company LTD. | $279.80 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $255.58 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $238.64 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.51 | 2022-2025 | Caplyta |
| Amgen INC. | $216.03 | 2019-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $208.07 | 2021 | |
| Mylan Specialty L.P. | $180.88 | 2021-2023 | Yupelri |
| Allergan, INC. | $161.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.92 | 2021-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $146.69 | 2025 | Voquezna |
| Antares Pharma, INC. | $136.88 | 2021-2022 | |
| Insulet Corporation | $125.22 | 2023-2024 | Omnipod |
| Vanda Pharmaceuticals INC. | $124.97 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $114.16 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $107.16 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $100.87 | 2019-2022 | |
| Horizon Therapeutics Plc | $88.90 | 2021-2022 | |
| Amarin Pharma, INC. | $69.38 | 2019-2022 | |
| Astellas Pharma US INC | $67.95 | 2019-2021 | |
| Dexcom, INC. | $55.18 | 2023-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $45.76 | 2024 | |
| Boston Scientific Corporation | $41.05 | 2024-2025 | Varithena Administration Pack, Ams 700 |
| Viatris Specialty LLC | $40.29 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $34.53 | 2023-2024 | Quviviq |
| Medtronic, INC. | $28.45 | 2022-2024 | Intellis Adaptivestim |
| Eisai INC. | $26.83 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.71 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.81 | 2023 | |
| Fisher & Paykel Healthcare INC | $20.11 | 2021 | |
| Cequr Corporation | $19.79 | 2024 | Cequr Simplicity |
| Irhythm Technologies, INC. | $17.17 | 2024 | Zio Xt Patch, Zio Monitor |
| Currax Pharmaceuticals LLC | $15.49 | 2023 | Contrave, Nexlizet, Nexletol |
| Paratek Pharmaceuticals, INC. | $15.01 | 2024 | Nuzyra |
| Esperion Therapeutics, INC. | $14.43 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.23 | 2022 | |
| Medtronic USA, INC. | $12.92 | 2020 | |
| Clarus Therapeutics INC. | $4.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.